Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Fam Cancer. 2020 Jul;19(3):269-271. doi: 10.1007/s10689-020-00174-5. Epub 2020 Mar 21.
A 14-year-old male presented with abdominal pain. Imaging illustrated a left-sided adrenal mass; he underwent a left nephrectomy, confirming an extra-adrenal PGL. Germline genetic testing revealed a heterozygous, likely pathogenic mutation in the SDHB gene. The patient's family subsequently underwent genetic testing; his mother and sister were both positive for the familial SDHB mutation. Cascade testing for the proband's maternal aunt and maternal grandparents was negative for the familial mutation. SNP genotyping was used to confirm relationships. This is the second reported case of a de novo SDHB gene mutation and the first reported case of a confirmed de novo mutation in a patient who was not the initial proband. As SDHB-associated PGLs and PCCs are expected to be more aggressive and malignant, it is imperative to identify patients with SDHB mutations early. Given that many patients with germline mutations have no family history of PGL of PCC, the possibility of de novo mutations must be considered. Further studies are needed to determine the rate of de novo mutation in SDHB and other SDH-complex genes. Up to 41% of patients with paragangliomas (PGL) or pheochromocytomas (PCC) have an identifiable hereditary cancer predisposition syndrome. Mutations in 12 genes are known to increase the risk of PGL and/or PCC; however, the de novo rate is mostly unknown. Only one case report exists of a de novo SDHB mutation. We present the second case of a family with a de novo SDHB mutation.
一名 14 岁男性因腹痛就诊。影像学检查显示左侧肾上腺肿块;他接受了左肾切除术,证实为肾上腺外 PGL。种系基因检测显示 SDHB 基因存在杂合、可能致病的突变。随后,患者的家人接受了基因检测;他的母亲和妹妹均携带家族性 SDHB 突变。对先证者的姨母和外祖父母进行级联检测,未发现家族性突变。SNP 基因分型用于确认亲属关系。这是第二例报道的 SDHB 基因突变病例,也是首例报道的非初始先证者的明确新发突变病例。由于 SDHB 相关 PGL 和 PCC 预计更具侵袭性和恶性,因此必须尽早识别携带 SDHB 突变的患者。鉴于许多携带种系突变的患者没有 PGL 或 PCC 的家族史,必须考虑新发突变的可能性。需要进一步研究以确定 SDHB 和其他 SDH 复合物基因中的新发突变率。多达 41%的副神经节瘤 (PGL) 或嗜铬细胞瘤 (PCC) 患者存在可识别的遗传性癌症易感性综合征。已知 12 个基因的突变会增加 PGL 和/或 PCC 的风险;然而,新发突变率大多未知。仅有一例 SDHB 新发突变的病例报告。我们报告了第二个具有 SDHB 新发突变的家族病例。